
This study evaluates the use of zzso colony stimulating factor zzso in patients with prolonged zzso dysfunction zzso 21 zzso after using chemotherapy to treat zzso One hundred and seven patients were identified who had a zzso count below 1000 zzso more than 21 days after start of chemotherapy zzso zzso or after bone zzso transplantation zzso zzso There were 66 males and 40 females ranging in age from zzso to 82 zzso The duration of zzso was 48 zzso 43 days in the chemotherapy alone group, and 79 zzso 57 days in the post zzso zzso Over zzso of the patients had zzso zzso and zzso had an infection prior to the start of the zzso Patients received 5 zzso zzso body weight daily zzso or zzso for 14 zzso 11 days in the chemotherapy group and 20 zzso 26 days in the zzso zzso Sixty percent of chemotherapy patients and zzso of zzso patients had a zzso response to treatment zzso count zzso 2000 zzso Median times to zzso recovery were 7 days in the chemotherapy group and 10 days in the zzso zzso There was a significant reduction in the number of infections zzso to zzso in the chemotherapy zzso Clinical responses in the two groups were zzso and zzso zzso No zzso drug-related adverse events were reported and no evidence of stimulation of zzso clones was zzso It is concluded that zzso is effective and well tolerated in patients with prolonged bone zzso dysfunction after chemotherapy or zzso Although results from an zzso trial must be viewed with caution, this observation confirms the value and safety of zzso therapy in patients with this zzso and often zzso zzso 

